TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00819078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 300 mg/d
Study: NCT02646696

Intervention type: OTHER
Intervention: Sensory Challenge Protocol
Description: Measurement of electrodermal activity in response to sensation

Intervention type: OTHER
Intervention: Sensory Challenge Protocol
Description: Measurement of electrodermal activity in response to sensation
Study: NCT01358318

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Satiety
Description: Single consumption of snack bars to determine satiety and food intake at next meal.
Study: NCT00819078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no dosage
Study: NCT03530735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger-prick Autologous Blood (FAB)
Description: Patients will be instructed to use FAB therapy by:~1. Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.~2. Use a diabetic lancet to prick their cleaned fingertip.~3. Squeeze 5 drops of blood form their finger into 10ml of saline.~4. Gargle the blood-saline mixture for 5 minutes.~5. Swallow the blood-saline mixture.~6. Repeat this 4 times per day.
Study: NCT03473665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Study: NCT00979927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPC3649
Description: 5 weekly doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 5 weekly doses
Study: NCT03794154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta capsule
Description: Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride capsule
Description: Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
Study: NCT01262534

Intervention type: OTHER
Intervention: Clinical profile of patients
Description: Comorbidities and associated type of treatments will be collected.

Intervention type: OTHER
Intervention: Patient Preferences about treatment
Description: Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.

Intervention type: OTHER
Intervention: Quality of Life
Description: The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
Study: NCT02671097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788 (ODM-201)
Description: 600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
Study: NCT03261791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib mesylate tablets 500 mg po qd.
Study: NCT00874848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG Injection
Description: 4 mg/kg i.v. over 2 hrs, weekly, in three week cycles

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Study: NCT01358318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satiety
Description: Single consumption of snack bars to determine satiety and food intake at next meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satiety
Description: Single consumption of snack bars to determine satiety and food intake at next meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satiety
Description: Single consumption of snack bars to determine satiety and food intake at next meal.
Study: NCT01268384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Capecitabine
Description: Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
Study: NCT00874848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Study: NCT01907763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB07 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB07 400mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOTB 200mg placebo
Description: Placebo of SOTB07 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB 200mg placebo
Description: Placebo of SOTB07 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOTB 400mg placebo
Description: Placebo of SOTB07 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB 400mg placebo
Description: Placebo of SOTB07 400mg
Study: NCT00882960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous fentanyl
Description: An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-nasal fentanyl
Description: a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
Study: NCT03015753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list control group
Description: At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
Study: NCT04125342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preventive Conditioned NIV Therapy after planned extubation
Description: Conditioned NIV during 48 hours following extubation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preventive Conditioned NIV Therapy after planned extubation
Description: Conditioned NIV during 48 hours following extubation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Preventive HFOT after planned extubation
Description: HFOT set according to patients tolerance during 48 hours following extubation
Study: NCT02042924

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
Study: NCT01469286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEA
Description: Electroacupuncture at ST36

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-TEA
Description: Electroacupuncture at sham-points
Study: NCT02544529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echothiophate Iodide 0.03% Ophthalmic Solution
Description: one drop to each eye three times per week for 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboxymethylcellulose Sodium (0.5%)
Description: one drop to each eye three times per week for 18 weeks
Study: NCT01458899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Oral tablets, single 4mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Oral tablets, single 4mg dose
Study: NCT03001570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab plus Radiotherapy
Description: Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
Study: NCT03073096

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LVA at time of nodal dissection
Description: Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
Study: NCT04347265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
Study: NCT00612196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
Study: NCT04347265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
Study: NCT06106971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate
Description: Subjects receive sodium tetradecyl sulfate via balloon-occluded retrograde transvenous obliteration at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate
Description: Subjects receive endoscopic cyanoacrylate injection at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding then receive repeated endoscopic cyanoacrylate injection at 1-month intervals until obliteration of gastric varices.
Study: NCT00612196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
Study: NCT00159588

Intervention type: DRUG
Group type: OTHER
Intervention: Betablockers or other preventive drugs based on primary headache type
Description: Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)

Intervention type: DRUG
Group type: OTHER
Intervention: Betablockers or other preventive drugs based on primary headache type
Description: Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
Study: NCT04125342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Preventive HFOT after planned extubation
Description: HFOT set according to patients tolerance during 48 hours following extubation
Study: NCT00612196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00892710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5 IV every 21 days
Study: NCT02034838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir 300mg boosted with ritonavir 50 mg
Description: atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)
Study: NCT03348176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable exposure
Description: Repeated exposure to variety of vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable exposure
Description: Repeated exposure to variety of vegetables

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIPP-Feeding Infants
Description: Promoting responsive feeding practices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIPP-Feeding Infants
Description: Promoting responsive feeding practices

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Phone calls with mother about development of child, no advice on complementary feeding
Study: NCT02451124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-endoscopic inflatable balloon for the esophagus
Description: Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03193996

Intervention type: DEVICE
Group type: OTHER
Intervention: 4DCT
Description: 4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
Study: NCT02929017

Intervention type: OTHER
Group type: OTHER
Intervention: SUPPORT
Description: Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.

Intervention type: OTHER
Group type: OTHER
Intervention: Currently Available Printed Material
Description: Subjects will receive their usual standard of care, including currently available printed patient material.
Study: NCT02451124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagogastroduodenoscopy
Description: Standard of care, patients digestive tract scoped post balloon brushing
Study: NCT01247194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-461
Description: capsule, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-461
Description: capsule, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-461
Description: capsule, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsules, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsules, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsules, oral, once daily for 3 days
Study: NCT00897221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution 100mg/mL
Description: Deferiprone oral solution (20 mg/kg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution 100 mg/mL
Description: Deferiprone oral solution(40mg/kg/day)
Study: NCT00612521

Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine
Description: For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
Study: NCT00209040

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic Startle Testing
Description: See protocol description for methodological details

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic Startle Testing
Description: See protocol description for methodological details
Study: NCT02218034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190168 Formulation 1
Description: AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190168 Formulation 2
Description: AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tazarotene gel 0.1%
Description: Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Study: NCT06311422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin nanoceramic block
Description: Resin-based CAD/CAM materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zirconia-reinforced lithium silicate
Description: zirconia reinforced lithium silicate ceramic
Study: NCT04231604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Lust for Life
Description: A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in adolescents. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the adolescents' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list control
Description: Control group placed on a twelve-week waiting list.
Study: NCT02057159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroVax
Description: TCR peptides in IFA

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IFA Placebo
Description: IFA Placebo
Study: NCT02150915

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture therapy (leopard spot needling technique)
Description: Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (leopard spot needling technique)
Description: Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
Study: NCT02017925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo pulmonary rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo pulmonary rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary complications management/prevention
Description: Undergo pulmonary rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary complications management/prevention
Description: Undergo pulmonary rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies